Cystatin C concentration as a risk factor for heart failure in older adults.
BACKGROUND
Previous studies that evaluated the association of kidney function with incident heart failure may be limited by the insensitivity of serum creatinine concentration for detecting abnormal kidney function.


OBJECTIVE
To compare serum concentrations of cystatin C (a novel marker of kidney function) and creatinine as predictors of incident heart failure.


METHODS
Observational study based on measurement of serum cystatin C from frozen sera obtained at the 1992-1993 visit of the Cardiovascular Health Study. Follow-up occurred every 6 months.


METHODS
Adults 65 years of age or older from 4 communities in the United States.


METHODS
4384 persons without previous heart failure who had measurements of serum cystatin C and serum creatinine.


METHODS
Incident heart failure.


RESULTS
The mean (+/-SD) serum concentrations of cystatin C and creatinine were 82 +/- 25 nmol/L (1.10 +/- 0.33 mg/L) and 89 +/- 34 micromol/L (1.01 +/- 0.39 mg/dL), respectively. During a median follow-up of 8.3 years (maximum, 9.1 years), 763 (17%) participants developed heart failure. After adjustment for demographic factors, traditional and novel cardiovascular risk factors, cardiovascular disease status, and medication use, sequential quintiles of cystatin C concentration were associated with a stepwise increased risk for heart failure in Cox proportional hazards models (hazard ratios, 1.0 [reference], 1.30 [95% CI, 0.96 to 1.75], 1.44 [CI, 1.07 to 1.94], 1.58 [CI, 1.18 to 2.12], and 2.16 [CI, 1.61 to 2.91]). In contrast, quintiles of serum creatinine concentration were not associated with risk for heart failure in adjusted analysis (hazard ratios, 1.0 [reference], 0.77 [CI, 0.59 to 1.01], 0.85 [CI, 0.64 to 1.13], 0.97 [CI, 0.72 to 1.29], and 1.14 [CI, 0.87 to 1.49]).


CONCLUSIONS
The mechanism by which cystatin C concentration predicts risk for heart failure remains unclear.


CONCLUSIONS
The cystatin C concentration is an independent risk factor for heart failure in older adults and appears to provide a better measure of risk assessment than the serum creatinine concentration. *For a full list of participating Cardiovascular Health Study investigators and institutions, see http://www.chs-nhlbi.org.
Sarnak
Mark J
MJ
Tufts-New England Medical Center, Boston, Massachusetts, USA.
Katz
Ronit
R
Stehman-Breen
Catherine O
CO
Fried
Linda F
LF
Jenny
Nancy Swords
NS
Psaty
Bruce M
BM
Newman
Anne B
AB
Siscovick
David
D
Shlipak
Michael G
MG
D000368:Aged; D015415:Biomarkers / Q000097:blood; D003404:Creatinine / Q000097:blood; D055316:Cystatin C; D015891:Cystatins / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006333:Heart Failure / Q000097:blood* / Q000453:epidemiology* / Q000503:physiopathology; D006801:Humans; D015994:Incidence; D007668:Kidney / Q000503:physiopathology; D007677:Kidney Function Tests / Q000379:methods*; D008297:Male; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D015415:Biomarkers; C525030:CST3 protein, human; D055316:Cystatin C; D015891:Cystatins; D003404:Creatinine